WO2003029477A1 - Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid - Google Patents
Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid Download PDFInfo
- Publication number
- WO2003029477A1 WO2003029477A1 PCT/EP2002/010511 EP0210511W WO03029477A1 WO 2003029477 A1 WO2003029477 A1 WO 2003029477A1 EP 0210511 W EP0210511 W EP 0210511W WO 03029477 A1 WO03029477 A1 WO 03029477A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- amino
- tert
- reaction
- alkyl
- Prior art date
Links
- YJYCHJJVAXTSAH-JTQLQIEISA-N CC(C)(C)OC(N[C@@H](CSc(c(N)c1)ccc1C(O)=O)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CSc(c(N)c1)ccc1C(O)=O)C(O)=O)=O YJYCHJJVAXTSAH-JTQLQIEISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
Definitions
- the present invention relates to a new enzymatic process for the preparation of compqunds of formula I
- R 1 is hydrogen or alkyl
- R is an ammo protecting group; each R 3 is independently halogen, carboxyl, alkoxycarbonyl, alkenyloxycarbonyl or benzyloxycarbonyl; n is 1 or 2.
- EP 0407033 A an enzymatic stereoselective hydrolysis of racemic mixtures of esters of 2-substituted acids, other than 2-halo propionic acids, into the corresponding enantiomeric acids is described.
- the reaction is carried out in the presence of Candida rugosa lipase isoenzymes, an organic solvent (e.g. toluene) and a reducing agent.
- the process is especially useful for the stereoselective production of S-ketoprofen, S-ibuprofen, S-fenoprofen, S-2-phenylpropionic acid and S-indoprofen.
- EP 0178553 A the preparation of aromatically substituted L-amino acids by selective hydrolysis of the corresponding alkyl esters with chymotrypsin is described.
- the aim of the present invention therefore is a novel and inventive process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acids.
- the compounds of formula I may be manufactured by the process of the present invention, which provides a new process for the preparation of substituted 2-amino-3-(2- amino-phenylsulfanyl) -propionic acid of formula I
- R 1 is hydrogen or alkyl; R is an amino protecting group; each R is independently halogen, carboxyl, alkoxycarbonyl, alkenyloxycarbonyl or benzyloxycarbonyl; n is 1 or 2,
- R 4 is alkyl or benzyl, with a protease in an aqueous system containing an organic co-solvent.
- alkyl denotes an optionally substituted straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl including their different isomers.
- Suitable substituents for the alkyl chain may be selected from 1-3 halogens such as fluorine or chlorine, or . 4 -alkoxy such as methoxy or ethoxy.
- Examples for substituted alkyl are 2-chloroethyl, 2-fluoroefhyl, 2,2,2-trifluoroethyl or 2-methoxyethyl.
- Alkyl in R 1 is as defined above and preferably a straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms.
- Alkyl in R is more preferred methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert.-butyl.
- Alkyl in R 4 is as defined above and preferably an optionally substituted straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms.
- Suitable substituents for the alkyl chain may be selected from 1-3 halogen such as fluorine or chlorine, or C ⁇ ._- alkoxy such as methoxy or ethoxy.
- alkyl in R 4 is more preferred a straight chain hydrocarbon residue containing 1 to 7 or 1 to 4 carbon atoms. Examples are methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl. Preferred examples are methyl, ethyl or propyl. Most preferred alkyl in R 4 is methyl.
- amino protecting group refers to groups such as those employed in peptide chemistry as described in Green T. Protective Groups in Organic Synthesis, Chapter 5, John Wiley and Sons, Inc. (1981), pp. 218-287, such as an allyloxycarbonyl group (ALLOC), a lower alkoxycarbonyl group (e.g. tert.-butoxycarbonyl (t-BOC)), a substituted lower alkoxycarbonyl group (e.g. trichloroethoxycarbonyl), an optionally substituted aryloxycarbonyl group (e.g.
- ALLOC allyloxycarbonyl group
- t-BOC lower alkoxycarbonyl group
- t-BOC substituted lower alkoxycarbonyl group
- aryloxycarbonyl group e.g.
- p-nitrobenzyloxycarbonyl benzyloxycarbonyl (Z) or phenyloxycarbonyl
- an alkanoyl group e.g. formyl, acetyl
- an aroyl group e.g. benzoyl
- a halogen-alkanoyl group e.g. trifluoroacetyl
- a silyl protective group e.g. tert.-butyldimethylsilyl.
- Preferred amino protecting groups are benzyloxycarbonyl, tert.-butoxycarbonyl, allyloxycarbonyl or benzoyl, especially preferred amino protecting group is tert.-butoxycarbonyl.
- alkoxy groups are methoxy, ethoxy, n-propyloxy, iso- propyloxy, n-butyloxy, 1-sec-butyloxy, iso-butyloxy, tert.-butyloxy, pentyloxy, hexyloxy, heptyloxy including their different isomers.
- alkoxycarbonyl groups are methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert.-butoxycarbonyl and the like. Preferred lower alkoxycarbonyl is tert.-butoxycarbonyl.
- alkenyl as used herein denotes an unsubstituted or substituted hydrocarbon chain radical having from 2 to 8 carbon atoms, preferably from 2 to 4 carbon atoms, and having at least one olefinic double bond, including their different isomers. Examples are vinyl, allyl or isopropenyl.
- alkenyloxycarbonyl for R 3 is allyloxycarbonyl or isopropenyloxycarbonyl, more preferred is allyloxycarbonyl.
- halogen signifies fluorine, chlorine, bromine or iodine. Preferred halogen is bromine.
- the number n maybe either 1 or 2, preferably the number n is 1.
- the substituent R may be in any possible position attached to the phenyl ring. If n is 1, R 3 may be in the 3,4,5 or 6-position of the phenyl ring. Preferably, the R 3 substituent is in the 4-position. If n is 2, both R 3 substituents may be in the independently from each other in the 3,4,5 or 6-position of the phenyl ring.
- a preferred embodiment of the invention is a process for the preparation of compounds of formula I, characterized in that compound of formula II is
- R , ⁇ 1 , R , R 3 , R 4 and n are as defined above.
- R 1 is hydrogen or alkyl, more preferred
- R 1 is hydrogen; R is an amino protecting group, more preferred
- R is an amino protecting group; each R 3 is independently halogen, carboxyl or alkenyloxycarbonyl;
- R 4 is alkyl or benzyl, more preferred
- R 4 is alkyl; n is 1 or 2, more preferred n is 1.
- the process is carried out with a protease in an aqueous system, containing an organic co-solvent, at a pH of 4.0 - 10, preferred 6.0 - 8.5.
- the enantiomeric pure product of formula I is separated by acidification and subsequent extraction.
- Compound of formula II may be used in any possible mixture of the L or D enantiomers. The conversion is accomplished preferably with a racemic mixture or with a mixture which only contains the L-isomer.
- the unreacted remaining D-ester is removed by an extraction step prior to acidification of the reaction medium and subsequent extraction of the L-acid.
- proteases preferably cheap bulk proteases of microbial origin, more preferred are Bacillus proteases (like Savinase from Novo Nordisk) or subtilisins e.g. subtilisin Carlsberg from Novo Nordisk (Alkalase) or from Solvay (Protease-L) or Aspergillus proteases (like Prozyme 6 from Amano) or
- Bacillus proteases like Savinase from Novo Nordisk
- subtilisins e.g. subtilisin Carlsberg from Novo Nordisk (Alkalase) or from Solvay (Protease-L) or Aspergillus proteases (like Prozyme 6 from Amano) or
- Tritachium proteases (Proteinase K from Fluka). Most preferred enzyme as catalyst for the reactions is subtilisin Carlsberg (e.g. Alcalase from Novo Nordisk).
- enzymes may be used in immobilized form.
- the reaction is carried out in an aqueous system with an organic co-solvent, such as a water-immiscible solvent or a water-miscible organic co-solvent.
- an organic co-solvent such as a water-immiscible solvent or a water-miscible organic co-solvent.
- the water-immiscible solvent maybe used in any ratio with the aqueous phase, preferred ratio is 25-75% (v/v).
- the water-miscible organic co-solvent may be used in an amount as high as tolerated by the enzyme, typically 5-25% (v/v) but which might exceed even 50%) (v/v), e.g. in case of subtilisin Carlsberg.
- the reaction is carried out at a reaction temperature from 0°C to 50°C, preferred at a reaction temperature between 15°C and 40°C, and most preferred at a reaction temperature between 15°C and 25°C.
- aqueous phase common buffer solutions known in the art for biochemical conversions may be used, such as sodium or potassium phosphate in a concentration of up to 1M, preferably between about 5mM and about 50mM.
- a buffer solution may additionally contain one of the usual salts like e.g. sodium or potassium chloride, and also LiSCN, Na 2 SO 4 or a polyhydric alcohol e.g. a sugar; in a concentration up to 1M.
- Suitable organic co-solvents are technically common solvents. Examples are ethers (e.g. tetrahydrofuran (THF), dioxan or tert.-butyl methyl ether (TBME)), lower alcohols, esters (e.g. ethyl acetate), polar aprotic solvents (e.g. dimethylsulfoxide (DMSO), dimethylacetamide, N.N-dimethylformamide (DMF) or acetone).
- Preferred organic co- solvents are tetrahydrofuran (THF), tert.-butyl methyl ether (TBME) and ethyl acetate.
- lower alcohol denotes straight chain or branched alkyl residues containing 1 to 8 carbon atoms with one hydroxy group, such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert.-butanol, pentanol, hexanol, heptanol or octanol, preferably methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert.-butanol and more preferred alcohol are methanol or ethanol.
- the substrate is suitably applied as a solution in a 0.1 - 25% overall concentration (w/w). A more preferred overall concentration is 1 - 10%).
- the pH of the reaction mixture is maintained under vigorous stirring at the selected pH-value by the controlled addition of a base.
- Preferred bases are aqueous NaOH or KOH solutions.
- the enantiomerically pure product of formula I is worked up conventionally after phase separation, by acidification of the aqueous phase with a suitable acid and subsequent extraction with a suitable organic solvent.
- R > ⁇ , ⁇ R2 , R.3 and R are as described for compounds of formula I and II.
- substituted 2-nitro fluoro-aromatic of formula a) is reacted with protected cysteine (e.g. BOC-Cysteine-methylester) of formula b) to obtain the corresponding nitro-phenyl substituted protected cysteine of formula c).
- protected cysteine e.g. BOC-Cysteine-methylester
- the reaction is conveniently carried out under basic conditions (with a diisopropylamine, e.g. ethyldiisopropylamine) in an appropriate organic solvent, such as hexane, diisopropylether, ethyl acetate, methanol, ethanol, propanol, dichloromethane, DMF or DMSO.
- the reaction temperature is preferably between -30°C to +150°C.
- the reaction is carried out with BOC-Cysteine-methylester in ethanol in the presence of ethyldiisopropylamine at a temperature of 110°C.
- Compounds of formula a) and the protected cysteine (e.g. BOC-Cysteine- methylester) of formula b) are commercially available or synthesized according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry : Reactions, Mechanisms, and Structure", C ed. John Wiley & Sons).
- the second step of the reaction is carried out in that the nitro group of the nitro- phenyl substituted protected cysteine of formula c) is reduced to the corresponding amino-phenyl substituted protected cysteine of formula II.
- the reduction reaction is carried out according to methods known in the art for example known in textbooks on organic chemistry e.g. J. March (1992), "Advanced Organic Chemistry : Reactions, Mechanisms, and Structure", 4 l ed. John Wiley 8c Sons).
- the reaction is conveniently carried out with a suitable reducing agent (e.g.
- Zinc and optional NH 4 C1) in acidic media with organic solvents such as hexane, diisopropylether, ethyl acetate, methanol, ethanol, propanol, dichloromethane, DMF, DMSO, preferably methanol.
- organic solvents such as hexane, diisopropylether, ethyl acetate, methanol, ethanol, propanol, dichloromethane, DMF, DMSO, preferably methanol.
- the reaction temperature is preferably between -30°C to +150°C.
- the NH -group of compound of amino-phenyl substituted protected cysteine of formula II may be alkylated with RiHal, wherein Ri is as defined above and Hal is chlorine or bromine.
- Compounds of the formula I are versatile building blocks for the synthesis of 1,5- benzothiazepines.
- Such benzothiazepine scaffolds have been used as a constrained dipeptide mimics in various enzyme inhibitors (protease, interleukin-l ⁇ -converting enzyme, elastase or angiotensin-converting enzyme, but also as GPCR antagonists (cholecystokinin, angiotensin II receptor).
- enzyme inhibitors protease, interleukin-l ⁇ -converting enzyme, elastase or angiotensin-converting enzyme, but also as GPCR antagonists (cholecystokinin, angiotensin II receptor).
- GPCR antagonists cholecystokinin, angiotensin II receptor
- the benzothiazepines are prepared according reaction scheme 2:
- R , R , R , R and n are as described for compounds of formula I and II.
- the cyclisation reaction of compound of formula I to obtain benzothiazepine of formula III is carried out thermally or in the presence of an appropriate reagent, for example as described in G.C. Morton et al, Tet. Lett, 41 (2000) 3029-3033).
- the reaction is conveniently carried out with a carbodiimide in an appropriate solvent such as hexane, xylene, diisopropylether, ethyl acetate, methanol, ethanol, propanol, dichloromethane, DMF or DMSO.
- the reaction temperature is preferably between -30°C to +150°C.
- the reaction is preferably carried out at room temperature in DMF in the presence of ED AC (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride).
- ED AC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
- the biphasic reaction mixture was separated.
- the aqueous phase was washed briefly with 11 TBME for the separation of small amounts of lipophilic impurities and traces of the remaining substrate.
- the combined organic phases were extracted with 1 x 250ml 0.1 M potassium phosphate buffer pH 7.6.
- the combined aqueous phases were acidified to pH 2 with 32% hydrochloric acid and extracted with 1.51 ethyl acetate.
- the resulting emulsion was separated by the addition of 10% Dicalite under stirring and a subsequent filtration.
- the aqueous phase was extracted with 2 x 11 ethyl acetate.
- reaction mixture was acidified to pH 2 with 32% hydrochloric acid, filtered over Decalite. After phase separation the aqueous phase was extracted with 3 x 275ml ethyl acetate. The combined organic phases were dried on anhydrous sodium sulfate and evaporated. The residue was dissolved in dichloromethane, evaporated and dried at HV to give 1.56g N-tert.- butoxycarbonyl-3-(2-amino-4-bromophenylthio)-L-alanine as a pale yellow solid (yield: 99.8%o).
- aqueous phase was extracted once with 11 TBME.
- the combined TBME phases were extracted with 2 x 0.41 0.1 M potassium phosphate buffer pH 7.6.
- the combined aqueous phases were acidified to pH 2 with 32%> hydrochloric acid and extracted with 3 x 0.51 ethyl acetate.
- the phase separation was achieved by filtration on Dicalite.
- the combined ethyl acetate phases were dried on anhydrous sodium sulfate and evaporated.
- the reaction mixture was extracted with 100ml TBME. After phase separation the aqueous phase was acidified to pH 2.3 with 32% hydrochloric acid and extracted with 3 x 250ml ethyl acetate. In case a stabile emulsion was formed the phase separation was achieved by filtration on Dicalite. The combined ethyl acetate extracts were dried on anhydrous sodium sulfate and evaporated. The residue was dissolved in dichloromethane, evaporated and dried at HV to give 604mg N- tert.-butoxycarbonyl-3-(4-alloxycarbonyl-2- aminophenylthio)-L-alanine as a pale yellow solid (yield: 93.9%o, purity: 95%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02779375T DK1434870T3 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for preparing substituted 2-amino-3- (2-amino-phenylsulfanyl) -propionic acid |
MXPA04002694A MXPA04002694A (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid. |
DE60217145T DE60217145T2 (en) | 2001-09-25 | 2002-09-19 | ENZYMATIC PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-AMINO-3- (2-AMINO-PHENYLSULFANYL) -PROPIONIC ACID |
EP02779375A EP1434870B1 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid |
JP2003532690A JP4359142B2 (en) | 2001-09-25 | 2002-09-19 | Enzymatic method for the preparation of substituted 2-amino-3- (2-amino-phenylsulfanyl) propionic acid |
HU0401500A HU228360B1 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid |
KR1020047004254A KR100882972B1 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-2-amino-phenylsulfanyl-propionic acid |
IL16052702A IL160527A0 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3 (2-aminophenylsulfanyl)-propionic acid |
CA2461296A CA2461296C (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid |
IL160527A IL160527A (en) | 2001-09-25 | 2004-02-23 | Enzymatic process for the preparation of substituted 2 - amino - 3 (2 - aminophenylsulfanyl) -propionic acid and intermediates therefor and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01122906 | 2001-09-25 | ||
EP01122906.9 | 2001-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003029477A1 true WO2003029477A1 (en) | 2003-04-10 |
Family
ID=8178714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/010511 WO2003029477A1 (en) | 2001-09-25 | 2002-09-19 | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid |
Country Status (15)
Country | Link |
---|---|
US (1) | US7011960B2 (en) |
EP (1) | EP1434870B1 (en) |
JP (1) | JP4359142B2 (en) |
KR (1) | KR100882972B1 (en) |
CN (1) | CN100413972C (en) |
AT (1) | ATE349545T1 (en) |
CA (1) | CA2461296C (en) |
DE (1) | DE60217145T2 (en) |
DK (1) | DK1434870T3 (en) |
ES (1) | ES2278061T3 (en) |
HU (1) | HU228360B1 (en) |
IL (2) | IL160527A0 (en) |
JO (1) | JO2426B1 (en) |
MX (1) | MXPA04002694A (en) |
WO (1) | WO2003029477A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3067430A4 (en) * | 2013-11-01 | 2017-08-02 | Glytech, Inc. | Method for producing d-form or l-form amino acid derivative having thiol group |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
CN104404098A (en) * | 2014-12-15 | 2015-03-11 | 苏州汉酶生物技术有限公司 | Biological preparation method of lipoic acid |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2804892A1 (en) * | 1977-02-09 | 1978-08-10 | Procter & Gamble | PROCESS FOR THE PRODUCTION OF L-THREONINE AND ITS N-ACYL DERIVATIVE |
EP0178553A2 (en) * | 1984-10-18 | 1986-04-23 | Hoechst Aktiengesellschaft | Process for the production of aromatic substituted L-amino acids |
EP0407033A2 (en) * | 1989-06-05 | 1991-01-09 | Rhone-Poulenc Inc. | Lipase and isozymes, notably of Candida rugosa, and their use |
DE4009891A1 (en) * | 1990-03-28 | 1991-10-02 | Guenter Erich Prof Dr Jeromin | Prepn. of optically active alcohol(s) and carbonic acid di:ester(s) - by hydrolysis of racemic carbonic acid di:ester(s) with lipase |
EP0560408A1 (en) * | 1988-08-30 | 1993-09-15 | G.D. Searle & Co. | Enantio- and regioselective syntheses of organic compounds using enol esters as irreversible transacylation reagents |
EP0577253A2 (en) * | 1992-06-19 | 1994-01-05 | Bend Research, Inc. | Enantiomeric enrichment of (R,S)-3-quinuclidinol |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN87108140A (en) * | 1987-12-17 | 1988-10-19 | 山西省生物研究所 | The manufacture method of D-2 amino acids |
ZA925360B (en) * | 1991-07-17 | 1993-06-14 | Smithkline Beecham Corp | Retroviral protease inhibitors. |
DE4445954A1 (en) * | 1994-12-22 | 1996-06-27 | Abb Management Ag | Waste incineration process |
SK284594B6 (en) * | 1997-11-27 | 2005-07-01 | Lonza Ag | Process for the preparation of aminoalcohol derivatives and their salts |
DK1148140T3 (en) * | 2000-04-19 | 2007-01-08 | Basilea Pharmaceutica Ag | Process for the preparation of D-asparagine derivatives |
-
2002
- 2002-09-19 CN CNB02817772XA patent/CN100413972C/en not_active Expired - Fee Related
- 2002-09-19 DE DE60217145T patent/DE60217145T2/en not_active Expired - Lifetime
- 2002-09-19 IL IL16052702A patent/IL160527A0/en unknown
- 2002-09-19 CA CA2461296A patent/CA2461296C/en not_active Expired - Fee Related
- 2002-09-19 DK DK02779375T patent/DK1434870T3/en active
- 2002-09-19 EP EP02779375A patent/EP1434870B1/en not_active Expired - Lifetime
- 2002-09-19 MX MXPA04002694A patent/MXPA04002694A/en active IP Right Grant
- 2002-09-19 HU HU0401500A patent/HU228360B1/en not_active IP Right Cessation
- 2002-09-19 AT AT02779375T patent/ATE349545T1/en active
- 2002-09-19 KR KR1020047004254A patent/KR100882972B1/en not_active IP Right Cessation
- 2002-09-19 JP JP2003532690A patent/JP4359142B2/en not_active Expired - Fee Related
- 2002-09-19 WO PCT/EP2002/010511 patent/WO2003029477A1/en active IP Right Grant
- 2002-09-19 ES ES02779375T patent/ES2278061T3/en not_active Expired - Lifetime
- 2002-09-23 US US10/252,971 patent/US7011960B2/en not_active Expired - Lifetime
- 2002-09-24 JO JO200294A patent/JO2426B1/en active
-
2004
- 2004-02-23 IL IL160527A patent/IL160527A/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2804892A1 (en) * | 1977-02-09 | 1978-08-10 | Procter & Gamble | PROCESS FOR THE PRODUCTION OF L-THREONINE AND ITS N-ACYL DERIVATIVE |
EP0178553A2 (en) * | 1984-10-18 | 1986-04-23 | Hoechst Aktiengesellschaft | Process for the production of aromatic substituted L-amino acids |
EP0560408A1 (en) * | 1988-08-30 | 1993-09-15 | G.D. Searle & Co. | Enantio- and regioselective syntheses of organic compounds using enol esters as irreversible transacylation reagents |
EP0407033A2 (en) * | 1989-06-05 | 1991-01-09 | Rhone-Poulenc Inc. | Lipase and isozymes, notably of Candida rugosa, and their use |
DE4009891A1 (en) * | 1990-03-28 | 1991-10-02 | Guenter Erich Prof Dr Jeromin | Prepn. of optically active alcohol(s) and carbonic acid di:ester(s) - by hydrolysis of racemic carbonic acid di:ester(s) with lipase |
EP0577253A2 (en) * | 1992-06-19 | 1994-01-05 | Bend Research, Inc. | Enantiomeric enrichment of (R,S)-3-quinuclidinol |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3067430A4 (en) * | 2013-11-01 | 2017-08-02 | Glytech, Inc. | Method for producing d-form or l-form amino acid derivative having thiol group |
US10047042B2 (en) | 2013-11-01 | 2018-08-14 | Glytech, Inc. | Method for producing D-form or L-form amino acid derivative having thiol group |
Also Published As
Publication number | Publication date |
---|---|
CN100413972C (en) | 2008-08-27 |
IL160527A (en) | 2010-05-31 |
US20030119152A1 (en) | 2003-06-26 |
DK1434870T3 (en) | 2007-04-30 |
CA2461296A1 (en) | 2003-04-10 |
ES2278061T3 (en) | 2007-08-01 |
IL160527A0 (en) | 2004-07-25 |
HUP0401500A3 (en) | 2005-11-28 |
DE60217145T2 (en) | 2007-10-25 |
HU228360B1 (en) | 2013-03-28 |
US7011960B2 (en) | 2006-03-14 |
DE60217145D1 (en) | 2007-02-08 |
JP4359142B2 (en) | 2009-11-04 |
EP1434870A1 (en) | 2004-07-07 |
KR20040044979A (en) | 2004-05-31 |
MXPA04002694A (en) | 2004-06-18 |
KR100882972B1 (en) | 2009-02-12 |
EP1434870B1 (en) | 2006-12-27 |
JO2426B1 (en) | 2008-04-17 |
CN1553959A (en) | 2004-12-08 |
JP2005503830A (en) | 2005-02-10 |
CA2461296C (en) | 2011-07-05 |
HUP0401500A2 (en) | 2005-02-28 |
ATE349545T1 (en) | 2007-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3386955B1 (en) | Intermediates for the preparation of sacubitril and their preparation | |
KR20040017277A (en) | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | |
SK802004A3 (en) | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | |
CA2461296C (en) | Enzymatic process for the preparation of substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acid | |
US6261830B1 (en) | Enzymatic process for stereoselective preparation of a tertiary acid | |
US6639094B2 (en) | Process for producing α-aminoketone derivatives | |
EP1114047B1 (en) | An improved process for the preparation of thiazolidine-2,4-dione derivatives | |
EP2038260B1 (en) | Stereoselective synthesis of (s)-1-methyl-3-phenylpiperazine | |
US6069272A (en) | Simplified method for the production of vinyl glycine (2-aminobut-3-enoic acid) and a convenient resolution of a derivative | |
JP3819082B2 (en) | Optically active 3-N-substituted aminoisobutyric acids and salts thereof and process for producing them | |
US6239308B1 (en) | Method for producing α-hydroxy-β-aminocarboxylic acids | |
EP0239122B1 (en) | Process for the enzymatic resolution of racemic 2-amino-1-alkanols | |
US20050119341A1 (en) | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | |
US7012152B2 (en) | Method for producing lysine derivative | |
JP3855317B2 (en) | Process for producing α-hydroxy-β-aminocarboxylic acid | |
JP4476963B2 (en) | Optically active 3-N-substituted aminoisobutyric acids and salts thereof and process for producing them | |
WO2005123932A2 (en) | Process for the preparation of optically active alpha-substituted carboxylic acids or alpha-substituted carboxylic acid amides from enantiomeric mixtures of alpha-substituted carboxylic acid amides employing pseudomonas fluorescens | |
JP2002234881A (en) | Method for producing optically active 5,5-dimethyl-1,3- thiazolidine-4-craboxylic acid derivative | |
JPH05211891A (en) | Method for producing optically active vinyl glycine in form liberated or protected by enzymatic subject selecting hydrolysis | |
MXPA98007922A (en) | Enzimative process for the stereoselective preparation of amidas terapeuti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 160527 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002817772X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002779375 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/002694 Country of ref document: MX Ref document number: 2461296 Country of ref document: CA Ref document number: 598/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047004254 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003532690 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002779375 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002779375 Country of ref document: EP |